tert-Butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate

Catalog No. :
ACLTHN143
CAS No. :
898157-46-5
Molecular Formula :
C13H22BrNO3
Molecular Weight :
320.23

IUPAC Name:tert-butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate

tert-Butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$206.00Login to see priceIn stockInquiry
250mg97%$409.00Login to see priceIn stockInquiry
1g97%$832.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate
IUPAC Nametert-butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate
MDL No.MFCD08098461
Molecular FormulaC13H22BrNO3
Molecular Weight320.23
SMILESO=C(N(CC1)CCC21CC(Br)CO2)OC(C)(C)C
InChI KeyOWIBUDVDBOTXOB-UHFFFAOYSA-N
Synonym1-Oxa-8-azaspiro[4,5]decane-8-carboxylic acid,3-bromo-,1,1-dimethylethylester;tert-butyl3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate;EOS-62193;3-Bromo-8-Boc-1-oxa-8-azaspiro[4.5]decane;tert-butyl 3-bromo-1-oxa-8-azaspiro[4.5]decane-8-carboxylate - [B26301]
CAS No.898157-46-5

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACLTHN143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMCIX903 route compound structure diagram
    ACMCIX903240401-09-6 In Stock
  4. Then
  5. ACLTHN143 route product structure diagram
    ACLTHN143898157-46-5 In Stock
Inquiry

2. ACLTHN143 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACLTHN143 route product structure diagram
    ACLTHN143898157-46-5 In Stock
Inquiry

Comments (0)